Dr. Reddy's Laboratories Ltd.

NSE: DRREDDY | BSE: 500124 | ISIN: INE089A01023 | Industry: Pharmaceuticals
| Falling Comet
4364.35 -131.80 (-2.93%)
NSE Jan 24, 2022 15:31 PM
Volume: 556.5K
 

4364.35
-2.93%

Financial Results

  • Gross profit margin for the quarter at 53.4%:
    • Decreased by ~50 bps over previous year majorly on account of price erosion and lower export benefits partially offset by leverage benefit on manufacturing overheads.
    • Increased by ~120 bps sequentially, driven majorly by leverage benefit on manufacturing overheads partially offset by price erosion.
    • Gross profit margin for GG and PSAI business segments are at 56.9% and 25.9% respectively.
  • Selling, general & administrative (SG&A) expenses at Rs. 16.0 billion, increased by 22% on a yearon-year basis and by 6% sequentially. This increase was in line with the business growth and primarily attributable to royalty on sales, annual increments, investments in sales & marketing of our key brands and investments in digitalization.
  • Research & development {R&D) expenses at Rs. 4.5 billion. As % to revenues - Q2 FY22: 7.7% I Q1 FY22: 9.2% I Q2 FY21: 8.9%. We continue our focus on investing in R&D to build a healthy pipeline of new products across our markets including development of products in our biosimilars and generics businesses.
  • Other operating income at Rs. 1.7 billion compared to Rs. 149 million in Q2 FY21. The increase was on account of recognition of income towards sale of all of our rights relating to our anti-cancer agent E7777 (denileukin diftitox) to Citius Pharmaceuticals, Inc.
  • Net Finance income at Rs. 319 million compared to Rs. 237 million in Q2 FY21.
  • Profit before Tax at Rs. 12. 7 billion, increased by 47% year-on-year and by 71 % sequentially.
  • Profit after Tax at Rs. 9.9 billion. The effective tax rate is 21.8% for the quarter.
  • Diluted earnings per share is at Rs. 59.65

Commenting on the results, Co-Chairman & MD, G V Prasad said " I am pleased with the improvement in the financial performance across our businesses. While we continue to strengthen our core businesses of generics and AP ls, we are also making investments in our long-term growth drivers and deeper innovation capabilities. Our focus remains on meeting unmet patient needs around the world in keeping with our purpose".

 

 

 

 

Result PDF

default
Dr. Reddy's Laboratories Ltd. is trading below all available SMAs
Recommended